JGC
CNTA

J. Goldman & Co’s Centessa Pharmaceuticals CNTA Stock Holding History

J. Goldman & Co’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.61M Buy
+40,500
New +$1.04M 0.05% 357
2025
Q2 		– Sell
-94,600
Closed -$1.36M – 484
2025
Q1 		$1.36M Buy
94,600
+26,900
+40% +$440K 0.03% 335
2024
Q4 		$1.13M Buy
+67,700
New +$1.12M 0.03% 317

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

J. Goldman & Co's CNTA Position: Q4 2025 in Review

J. Goldman & Co sold out of Centessa Pharmaceuticals (CNTA) in Q4 2025, closing a stake of 13,105 shares — an estimated $318K sold.

J. Goldman & Co first reported a position in CNTA in Q4 2024 and held it in 4 quarters. The position peaked at $2.76M in Q4 2024. 146 funds tracked by Wall St. Rank hold CNTA as of Q4 2025.

  • J. Goldman & Co reported no remaining Centessa Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • J. Goldman & Co sold 13,105 Centessa Pharmaceuticals shares in Q4 2025, an estimated $318K.
  • J. Goldman & Co first reported a position in Centessa Pharmaceuticals in Q4 2024 and held it in 4 quarters.
  • J. Goldman & Co's Centessa Pharmaceuticals position peaked at $2.76M in Q4 2024.
  • 146 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q4 2025.

Based on J. Goldman & Co's 13F filing for Q4 2025, filed 17 Feb 2026.